Holocene Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Holocene Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.2M	Buy	+600,000	New	+$9.94M	0.03%	314
2025 Q2	–	Sell	-188,989	Closed	-$7.38M	–	831
2025 Q1	$7.38M	Sell	188,989 -1,396,178	-88%	-$60.2M	0.02%	314
2024 Q4	$85.8M	Hold	1,585,167	–	–	0.27%	107
2024 Q3	$79.9M	Sell	1,585,167 -41,174	-3%	-$1.93M	0.32%	102
2024 Q2	$71.5M	Buy	1,626,341 +171,472	+12%	+$7.26M	0.3%	101
2024 Q1	$73.1M	Buy	1,454,869 +493,539	+51%	+$26.8M	0.27%	120
2023 Q4	$58.1M	Buy	961,330 +855,508	+808%	+$44.1M	0.23%	137
2023 Q3	$6.03M	Buy	+105,822	New	+$5.84M	0.03%	360

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Holocene Advisors's MLTX Position: Q1 2026 in Review

Holocene Advisors opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 600,000 shares worth $11.2M. The stake represents 0.03% of the portfolio and ranks #314 among its holdings. This is a return to the name: Holocene Advisors previously reported a position in MLTX as recently as Q1 2025.

Holocene Advisors first reported a position in MLTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $85.8M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Holocene Advisors held 600,000 shares of MoonLake Immunotherapeutics worth $11.2M as of Q1 2026.
MoonLake Immunotherapeutics was a new Holocene Advisors position in Q1 2026.
MoonLake Immunotherapeutics made up 0.03% of Holocene Advisors's portfolio in Q1 2026, its #314 holding.
Holocene Advisors first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 8 quarters since.
Holocene Advisors's MoonLake Immunotherapeutics position peaked at $85.8M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.